Oramed Pharmaceuticals (FRA:OJU1) ROC %: -7.55% (As of Mar. 2026)

What is Oramed Pharmaceuticals ROC %?

Oramed Pharmaceuticals FRA:OJU1 -0.63% 34 ROC % is -7.55% as of Mar. 2026. GuruFocus rates FRA:OJU1 with a GF Score™ of 34/100. The stock has 5 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Oramed Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -7.55%.

As of today (2026-07-06), Oramed Pharmaceuticals's WACC % is 43.60%. Oramed Pharmaceuticals's ROC % is -12.71% (calculated using TTM income statement data). Oramed Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Oramed Pharmaceuticals (FRA:OJU1) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Oramed Pharmaceuticals's WACC % is 43.60%. Oramed Pharmaceuticals's ROC % is -12.71% (calculated using TTM income statement data). Oramed Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Oramed Pharmaceuticals ROC % Related Terms

Oramed Pharmaceuticals ROC % Historical Data

* Premium members only.

The historical data trend for Oramed Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals ROC % Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Dec24

Dec25

ROC %

Get a 7-Day Free Trial

-114.47

-213.22

-27.29

-21.82

-22.70

Oramed Pharmaceuticals Quarterly Data
	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROC %	Get a 7-Day Free Trial															-124.49	-24.44	-10.47	-24.57	-7.55

34GF Score

Oramed Pharmaceuticals Inc FRA:OJU1

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Oramed Pharmaceuticals ROC % Calculation

Oramed Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

	ROC % (A: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2024 )	+	Invested Capital (A: Dec. 2025 ))	/ count )
=	-12.885 * ( 1 - 15.01% )	/	( (11.72	+	84.743)	/ 2 )
=	-10.9509615	/	48.2315
=	-22.70 %

where

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	148.29	-	5.223	-	( 135.543	-	max(0, 5.429	-	136.776	+	135.543	))
=	11.72

	Invested Capital		(A: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	197.158	-	14.901	-	( 107.513	-	max(0, 16.299	-	113.813	+	107.513	))
=	84.743

Oramed Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-12.66 * ( 1 - 22.51% )	/	( (84.743	+	175.107)	/ 2 )
=	-9.810234	/	129.925
=	-7.55 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	197.158	-	14.901	-	( 107.513	-	max(0, 16.299	-	113.813	+	107.513	))
=	84.743

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	232.553	-	7.633	-	( 56.952	-	max(0, 9.137	-	58.95	+	56.952	))
=	175.107

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -7.55% mean?

Oramed Pharmaceuticals (FRA:OJU1) has a ROC % of -7.55% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Oramed Pharmaceuticals and its competitors.

Is Oramed Pharmaceuticals' ROC % too high?

Oramed Pharmaceuticals' current ROC % is -7.55%. Overall, Oramed Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.

How does Oramed Pharmaceuticals' ROC % compare to EQ and HUMA?

Oramed Pharmaceuticals' ROC % of -7.55% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Oramed Pharmaceuticals and its competitors. Oramed Pharmaceuticals's current ROC % is -7.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Oramed Pharmaceuticals stock overvalued right now?

Oramed Pharmaceuticals (FRA:OJU1) has a current ROC % of -7.55%. The current ROC % is -7.55%. Oramed Pharmaceuticals' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Oramed Pharmaceuticals (FRA:OJU1), the current ROC % is -7.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oramed Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies EQ HUMA NBP DTIL ARCT MDWD UNCY PLX NGEN OKUR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges ORMP:USA ORMP:Israel OJU1:Germany

Address 1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

34GF Score

Get the complete analysis for FRA:OJU1

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.96

Price

View FRA:OJU1 Analysis

See ROC % data for all stocks →